Limits...
The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer.

Brockton NT, Gill SJ, Laborge SL, Paterson AH, Cook LS, Vogel HJ, Shemanko CS, Hanley DA, Magliocco AM, Friedenreich CM - BMC Cancer (2015)

Bottom Line: Despite decades of informative research, the effective prevention, prediction and treatment of these lesions remains elusive.These include the impact of lifestyle factors and inflammation on risk of bone metastases, the gene expression features of the primary tumour, the potential role for metabolomics in early detection of bone metastatic disease and the signalling pathways that drive the metastatic lesions in the bone.Recurrences are identified through medical chart abstractions.

View Article: PubMed Central - PubMed

Affiliation: Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Room 515C, Holy Cross Centre, 2210 2nd St, SW, Calgary, AB, T2S 3C3, Canada. nigel.brockton@albertahealthservices.ca.

ABSTRACT

Background: Bone is the most common site of breast cancer distant metastasis, affecting 50-70 % of patients who develop metastatic disease. Despite decades of informative research, the effective prevention, prediction and treatment of these lesions remains elusive. The Breast Cancer to Bone (B2B) Metastases Research Program consists of a prospective cohort of incident breast cancer patients and four sub-projects that are investigating priority areas in breast cancer bone metastases. These include the impact of lifestyle factors and inflammation on risk of bone metastases, the gene expression features of the primary tumour, the potential role for metabolomics in early detection of bone metastatic disease and the signalling pathways that drive the metastatic lesions in the bone.

Methods/design: The B2B Research Program is enrolling a prospective cohort of 600 newly diagnosed, incident, stage I-IIIc breast cancer survivors in Alberta, Canada over a five year period. At baseline, pre-treatment/surgery blood samples are collected and detailed epidemiologic data is collected by in-person interview and self-administered questionnaires. Additional self-administered questionnaires and blood samples are completed at specified follow-up intervals (24, 48 and 72 months). Vital status is obtained prior to each follow-up through record linkages with the Alberta Cancer Registry. Recurrences are identified through medical chart abstractions. Each of the four projects applies specific methods and analyses to assess the impact of serum vitamin D and cytokine concentrations, tumour transcript and protein expression, serum metabolomic profiles and in vitro cell signalling on breast cancer bone metastases.

Discussion: The B2B Research Program will address key issues in breast cancer bone metastases including the association between lifestyle factors (particularly a comprehensive assessment of vitamin D status) inflammation and bone metastases, the significance or primary tumour gene expression in tissue tropism, the potential of metabolomic profiles for risk assessment and early detection and the signalling pathways controlling the metastatic tumour microenvironment. There is substantial synergy between the four projects and it is hoped that this integrated program of research will advance our understanding of key aspects of bone metastases from breast cancer to improve the prevention, prediction, detection, and treatment of these lesions.

No MeSH data available.


Related in: MedlinePlus

B2B/AMBER participant recruitment. Eligible patients are identified by the ACRB through CoBRA processes, and the contact details of consenting biospecimen donors are sent to a recruitment database shared by both the AMBER and B2B study coordinators. Patients are invited to participate by each study, and if they agree, their information is then imported into the specific study database. Some information sharing occurs between the AMBER and B2B study database, such as whether or not shared questionnaires have been completed
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4496930&req=5

Fig4: B2B/AMBER participant recruitment. Eligible patients are identified by the ACRB through CoBRA processes, and the contact details of consenting biospecimen donors are sent to a recruitment database shared by both the AMBER and B2B study coordinators. Patients are invited to participate by each study, and if they agree, their information is then imported into the specific study database. Some information sharing occurs between the AMBER and B2B study database, such as whether or not shared questionnaires have been completed

Mentions: The recruitment of patients into the B2B Cohort was harmonized with recruitment for the Alberta Moving beyond Breast cancER (AMBER) study [92] because the potential participants are drawn from the same population of breast cancer patients (Fig. 4). If a patient agrees to be contacted regarding future research, contact details for all eligible patients are imported into the AMBER & B2B Recruitment Database. Patients are first invited to participate in the AMBER study so that their exercise assessments can be completed prior to the delivery of systemic therapy [92].Fig. 4


The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer.

Brockton NT, Gill SJ, Laborge SL, Paterson AH, Cook LS, Vogel HJ, Shemanko CS, Hanley DA, Magliocco AM, Friedenreich CM - BMC Cancer (2015)

B2B/AMBER participant recruitment. Eligible patients are identified by the ACRB through CoBRA processes, and the contact details of consenting biospecimen donors are sent to a recruitment database shared by both the AMBER and B2B study coordinators. Patients are invited to participate by each study, and if they agree, their information is then imported into the specific study database. Some information sharing occurs between the AMBER and B2B study database, such as whether or not shared questionnaires have been completed
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4496930&req=5

Fig4: B2B/AMBER participant recruitment. Eligible patients are identified by the ACRB through CoBRA processes, and the contact details of consenting biospecimen donors are sent to a recruitment database shared by both the AMBER and B2B study coordinators. Patients are invited to participate by each study, and if they agree, their information is then imported into the specific study database. Some information sharing occurs between the AMBER and B2B study database, such as whether or not shared questionnaires have been completed
Mentions: The recruitment of patients into the B2B Cohort was harmonized with recruitment for the Alberta Moving beyond Breast cancER (AMBER) study [92] because the potential participants are drawn from the same population of breast cancer patients (Fig. 4). If a patient agrees to be contacted regarding future research, contact details for all eligible patients are imported into the AMBER & B2B Recruitment Database. Patients are first invited to participate in the AMBER study so that their exercise assessments can be completed prior to the delivery of systemic therapy [92].Fig. 4

Bottom Line: Despite decades of informative research, the effective prevention, prediction and treatment of these lesions remains elusive.These include the impact of lifestyle factors and inflammation on risk of bone metastases, the gene expression features of the primary tumour, the potential role for metabolomics in early detection of bone metastatic disease and the signalling pathways that drive the metastatic lesions in the bone.Recurrences are identified through medical chart abstractions.

View Article: PubMed Central - PubMed

Affiliation: Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Room 515C, Holy Cross Centre, 2210 2nd St, SW, Calgary, AB, T2S 3C3, Canada. nigel.brockton@albertahealthservices.ca.

ABSTRACT

Background: Bone is the most common site of breast cancer distant metastasis, affecting 50-70 % of patients who develop metastatic disease. Despite decades of informative research, the effective prevention, prediction and treatment of these lesions remains elusive. The Breast Cancer to Bone (B2B) Metastases Research Program consists of a prospective cohort of incident breast cancer patients and four sub-projects that are investigating priority areas in breast cancer bone metastases. These include the impact of lifestyle factors and inflammation on risk of bone metastases, the gene expression features of the primary tumour, the potential role for metabolomics in early detection of bone metastatic disease and the signalling pathways that drive the metastatic lesions in the bone.

Methods/design: The B2B Research Program is enrolling a prospective cohort of 600 newly diagnosed, incident, stage I-IIIc breast cancer survivors in Alberta, Canada over a five year period. At baseline, pre-treatment/surgery blood samples are collected and detailed epidemiologic data is collected by in-person interview and self-administered questionnaires. Additional self-administered questionnaires and blood samples are completed at specified follow-up intervals (24, 48 and 72 months). Vital status is obtained prior to each follow-up through record linkages with the Alberta Cancer Registry. Recurrences are identified through medical chart abstractions. Each of the four projects applies specific methods and analyses to assess the impact of serum vitamin D and cytokine concentrations, tumour transcript and protein expression, serum metabolomic profiles and in vitro cell signalling on breast cancer bone metastases.

Discussion: The B2B Research Program will address key issues in breast cancer bone metastases including the association between lifestyle factors (particularly a comprehensive assessment of vitamin D status) inflammation and bone metastases, the significance or primary tumour gene expression in tissue tropism, the potential of metabolomic profiles for risk assessment and early detection and the signalling pathways controlling the metastatic tumour microenvironment. There is substantial synergy between the four projects and it is hoped that this integrated program of research will advance our understanding of key aspects of bone metastases from breast cancer to improve the prevention, prediction, detection, and treatment of these lesions.

No MeSH data available.


Related in: MedlinePlus